Trump touts 'promising' Pfizer coronavirus treatment under development
Antiviral compound eyed for possible clinical study
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here
President Trump said Pfizer’s efforts to develop COVID-19 treatments have shown “encouraging signs.”
Pfizer has been working to develop an antiviral compound to treat the coronavirus as well as a vaccine to prevent infection and other therapies. The company announced Thursday that it would perform pre-clinical studies on its antiviral compound and that it was investing in preparation for a possible clinical study later this year.
JOHNSON & JOHNSON CORONAVIRUS VACCINE COULD SCALE UP TO A BILLION DOSES BY END OF 2021: CEO
Trump, speaking at the White House during a coronavirus task force news conference, said it’s “a promising new treatment that might prevent the virus from replicating.”
“They have great feelings for this particular therapy,” he said.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| PFE | PFIZER INC. | 25.82 | -0.39 | -1.49% |
AMAZON TAKES ON CORONAVIRUS BY DEVELOPING TESTS FOR WIDE USE
There are now 19 therapies and treatments being tested through the FDA’s coronavirus treatment acceleration program and another 26 in the “active planning” for clinical trials, according to the president.
“Trials for Gilead’s antiviral drug Remdesivir continue and the company has also expanded emergency use for new patients – getting good early results by the way,” he said.
President Donald Trump speaks about the coronavirus in the James Brady Press Briefing Room of the White House, Thursday, April 9, 2020, in Washington. (AP Photo/Andrew Harnik)
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Drugmakers have also been “ramping up production” of hydroxychloroquine, Trump said. He has pointed to the malaria treatment as a potential therapy for COVID-19.
Even as pharmaceutical companies rush to develop a coronavirus cure, a treatment likely won’t be reaching most patients anytime soon. Several drug makers who have shared timelines for production have said they don’t expect to have vaccines available until sometime in 2021.
In the meantime, there are more than 1.5 million coronavirus cases worldwide, including more than 454,000 in the U.S., according to Johns Hopkins University data. More than 16,000 people have died from COVID-19 in the U.S., and worldwide the virus has killed more than 94,000.